

V. Allowable Subject Matter

The Applicants gratefully acknowledge the Examiner's indication that Claims 1-25 are allowed.

CONCLUSIONS

In light of the above Amendment and Remarks it is respectfully submitted that the present application is now in proper condition for allowance, and such action is earnestly solicited.

Should there be any minor issues outstanding in this matter, Examiner Delacroix-Muirheid is respectfully requested to telephone the undersigned attorney. Early passage of the subject application to issue is earnestly solicited.

Deposit Account

Applicants do not believe that any fee is associated with the submission of a response in this case. However, should Applicants be in error, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number **50-0426**.

Respectfully submitted,
JENKINS & WILSON, P.A.

Date: 2/6/2003

By: Sorajini Biswas
Sorajini J. Biswas
Registration No. 39,111

Suite 1400 University Tower
3100 Tower Boulevard
Durham, North Carolina 27707
Telephone: (919) 493-8000
Facsimile: (919) 419-0383

Customer Number Bar Code:



25297

421/60/15/2

SJB/ptw



Version With Markings To Show Changes Made


Deleted text is enclosed in brackets ([]). Text to be added is underlined and in bold typeface.


IN THE CLAIMS:

Please cancel Claims 26-48 and 50-57, without prejudice to the filing of one or more divisional applications thereon.


Please amend Claims 1, 3-12, 14-23, 49, 58 and 59 as follows:

1. A method of treating infection bursal disease (IBD) in an avian subject in need of such treatment, said method comprising administering to said subject a compound selected from the group consisting of:





(III)




(IV)

[and] or the pharmaceutically acceptable **[salt] salts** thereof, wherein :

p is an integer ranging from 1 to 8;


A is selected from O, S, and NR wherein R may be H or loweralkyl;

X', X'', X₃, X₄, X₅, X₆, R₁, **and** R₂ [, **R₃ and R₄**] are independently selected and each represented by loweralkyl, loweralkoxy, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, alkylaryl, halogen, or:




wherein each R₂₂ and R₂₃ **is** independently selected from the group consisting of H, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, and

alkylaryl, or two R_{22} groups together represent C_2 - C_{10} alkyl, hydroxyalkyl, or alkylene;
or the two R_{22} groups together represent cycloalkyl or:



wherein r is from 1 to 3 and R_{13} is H,




or $-CONHR_{10}NR_{11}R_{12}$, wherein:

R_{10} is loweralkyl; R_{11} and R_{12} are independently selected from the group consisting of H and lower alkyl; each R_8 is independently selected from the group consisting of H, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, and alkylaryl, or two R_8 groups together represent C_2 - C_{10} alkylene; R_9 is H, hydroxy, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, or alkylaryl; wherein X' and X'' may be in the meta or para positions;


X_1 and X_2 are independently selected from H, loweralkyl, or loweralkoxy;

and wherein said compound thereof is administered in an amount sufficient to treat IBD.


3. The method according to Claim 1, wherein said compound is represented by the formula:




4. The method according to Claim 1, wherein said compound is represented by the formula:




5. The method according to Claim 1, wherein said compound is represented by the formula:




6. The method according to Claim **[1] 5**, wherein said compound is represented by the formula:




7. The method according to Claim [1] 5, wherein said compound is represented by the formula:




8. The method according to Claim 1, wherein said compound is represented by the formula:




9. The method according to Claim 8, wherein said compound is represented by the formula:




10. The method according to Claim 1, wherein said compound is represented by the formula:




11. The method according to Claim 1, wherein said compound is represented by the formula:




12. The method according to Claim 1, wherein said compound is represented by the formula:




14. The method according to Claim 13, wherein said compound is represented by the formula:




15. The method according to Claim 14, wherein said compound is represented by the formula:




16. The method according to Claim 13, wherein said compound is represented by the formula:




17. The method according to Claim 16, wherein said compound is represented by the formula:




18. The method according to Claim 18, wherein said compound is represented by the formula:




19. The method according to Claim 13, wherein said compound is represented by the formula:




20. The method according to Claim 19, wherein said compound is represented by the formula:




21. The method according to Claim 19, wherein said compound is represented by the formula:







22. The method according to Claim 13, wherein said compound is represented by the formula:



23. The method according to Claim 22, wherein said compound is represented by the formula:



49. A pharmaceutical formulation for the treatment of infectious bursal virus disease (IBDV) in an avian subject, comprising a compound selected from the group consisting of:




[and] or the pharmaceutically acceptable salts thereof, wherein :


p is an integer ranging from 1 to 8;

A is selected from O, S, and NR wherein R may be H or loweralkyl;


X', X'', X₃, X₄, X₅, X₆, R₁, and R₂ [**R₃ and R₄**] are independently selected and each represented by loweralkyl, loweralkoxy, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, alkylaryl, halogen, or:



wherein each R₂₂ and R₂₃ is independently selected from the group consisting of H, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, and alkylaryl, or two R₂₂ groups together represent C₂-C₁₀ alkyl, hydroxyalkyl, or alkylene; or the two R₂₂ groups together represent cycloalkyl or:



wherein r is from 1 to 3 and R₁₃ is H,




or -CONHR₁₀NR₁₁R₁₂, wherein:


R_{10} is loweralkyl; R_{11} and R_{12} are independently selected from the group consisting of H and lower alkyl; each R_8 is independently selected from the group consisting of H, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, and alkylaryl, or two R_8 groups together represent C_2 - C_{10} alkylene; R_9 is H, hydroxy, loweralkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl, aryl, or alkylaryl; wherein X' and X'' may be in the meta or para positions;

X_1 and X_2 are independently selected from H, loweralkyl, or loweralkoxy; in a pharmaceutically acceptable carrier.


50. The pharmaceutical formulation according to Claim 49, wherein said compound is represented by the formula:




51. The pharmaceutical formulation according to Claim 50, wherein said compound is represented by the formula:




52. The pharmaceutical formulation according to Claim 49, wherein said compound is represented by the formula:




53. The pharmaceutical formulation according to Claim 52, wherein said compound is represented by the formula:




54. The pharmaceutical formulation according to Claim 52, wherein said compound is represented by the formula:




55. The pharmaceutical formulation according to Claim 49, wherein said compound is represented by the formula:




56. The pharmaceutical formulation according to Claim 55, wherein said compound is represented by the formula:



57. The pharmaceutical formulation according to Claim 55, wherein said compound is represented by the formula:



58. The pharmaceutical formulation according to Claim 49, wherein said compound is represented by the formula:



59. The pharmaceutical formulation according to Claim 58, wherein said compound is represented by the formula:

